pwshub.com

Shady drugmaker used code words to sell knockoff weight-loss drug: lawsuit

Starts with a T

Pivotal Peptides—which is not a licensed pharmacy or dispensary—did not respond to the letter. Instead, its website was modified to indicate that it was "down for maintenance," and the company instructed customers to email directly. About 10 days later, Pivotal Peptides' registered agent, Elizabeth Gately, then sent an email (which Lilly obtained) instructing customers to place tirzepatide orders using coded language.

"Good News," the email read, "Pivotal Peptides ... is still in business!"

"If a favorite product (starting with T) was your go-to, that name can’t be used in any correspondence with me or listed on my price sheet anymore," Gately allegedly wrote. "Therefore, I need another identifier and decided (for now) to call this peptide '11mg.'"

Gately went on to say that the codenamed product "is Pivotal Peptide’s [sic] bestseller," and "it is the only T size available from PP right now except by special order." The letter ended with: "Remember to order '11 mg' with the latest price to identify the product you want, if applicable, and no longer use T in our communication."

Pivotal Peptides did not respond to Ars' request for comment.

In a statement emailed to Ars, a Lilly spokesperson said Pivotal Peptides and the other companies Lilly is suing are engaging in "conduct that poses serious risks to patient safety." In the lawsuit, Lilly notes that even children could be ordering this DIY, research-grade drug.

"No one should ever be allowed to sell these untested, non-human grade or manipulated drugs to American consumers," the statement continued.

Lilly's lawsuits come amid a legal storm over compounded versions of the tirzepatide, which can be legally made by licensed pharmacies as long as tirzepatide is in shortage. On October 2, the Food and Drug Administration announced that the shortage had ended but then decided to reconsider the decision after being sued by compounding pharmacies.

On several occasions, the FDA has warned of safety concerns related to compounded versions of GLP-1 weight-loss drugs.

Source: arstechnica.com

Related stories
1 month ago - Selling online can be risky. Tech expert Kurt “CyberGuy" Knutsson helps you learn about marketplace scams and how to stay safe.
1 month ago - It's getting harder to spot, but here are some ways you can use ChatGPT to stop cheating and plagiarism.
1 month ago - The best antivirus software will protect your computer from virus attacks, malware and more. Here are the top picks tested by CNET experts.
1 month ago - Kaspersky is handing the computer security of US customers to UltraAV, an "alternative" product with unknown anti-malware capabilities. The move comes after US authorities banned its software, forcing it out of the US market. However,...
3 weeks ago - Tracking alternative is less invasive than other methods, but is opt out by default Privacy activist group noyb has filed a complaint against Mozilla over a "Privacy Preserving Attribution" feature that was quietly enabled in the Firefox...
Other stories
24 minutes ago - Middleware aimed at softening the shortage of AI accelerators Fujitsu has started selling middleware that optimizes the use of GPUs, so that those lucky enough to own the scarce accelerators can be sure they're always well-used.…
33 minutes ago - Fill the nutritional gaps in your diet with one of the best vitamin subscriptions, tested by our experts.
33 minutes ago - Stem cell editing, complete genome, and cane toad resistance mark necessary steps.
1 hour ago - Azure Blob Storage, AWS, and Twilio keys all up for grabs An analysis of widely used mobile apps offered on Google Play and the Apple App Store has found hardcoded and unencrypted cloud service credentials, exposing millions of users to...
1 hour ago - Looking to upgrade your shaving routine? Check out CNET’s picks for the best shave clubs of 2024 to take shaving to the next level.